Yuhan Corporation Shares Fall 2.98% to 75,000 Won... Kiwoom Securities: "Stock Expected to Trend Upward if Expanded Lazertinib Prescriptions Are Confirmed"
Yuhan Corporation's stock is declining in early trading on the 29th. Despite the company's third-quarter results largely meeting market expectations this year, concerns over the pace of royalty revenue inflows from the lung cancer drug Lazertinib and expectations regarding R&D achievements are weigh

Yuhan Corporation's stock is declining in early trading on the 29th. Despite the company's third-quarter results largely meeting market expectations this year, concerns over the pace of royalty revenue inflows from the lung cancer drug Lazertinib and expectations regarding R&D achievements are weighing on the share price.
As of the morning of the 29th, Yuhan Corporation (000100) is trading at 75,000 won, down 2,300 won from the previous trading day, a decline of 2.98%. The stock also closed 3.4% lower on the 28th, the day of the earnings announcement, continuing its weak performance.
■ Results Meet Expectations... What Lies Behind the Decline
Kiwoom Securities assessed that Yuhan's third-quarter 2026 results largely met market expectations. However, it pointed to the pace of running royalty inflows from Lazertinib and expectations for R&D achievements as the background for the stock's decline despite results not deviating significantly from market forecasts. Kiwoom Securities analyzed that the somewhat slow inflow of running royalties and the time needed for R&D outcomes to materialize are acting as burdens on the share price.
■ Lazertinib Royalties Key to Mid- to Long-Term Performance
Lazertinib is a treatment for non-small cell lung cancer developed by Yuhan. It is a targeted anticancer drug developed for non-small cell lung cancer patients with EGFR mutations, and after the technology was licensed to global pharmaceutical company Janssen, commercialization has been pursued in overseas markets. In the global market, combination therapy with amivantamab is drawing attention as one of the important treatment strategies.
An important part of Yuhan's mid- to long-term performance is royalty revenue from the expansion of global Lazertinib sales. Running royalties are revenues paid to the original developer based on the sales of the drug by the company that received the technology transfer, and unlike contract payments or milestone revenues at development stages that occur at specific points in time, they can be generated continuously based on sales performance.
Therefore, the expansion of overseas Lazertinib prescriptions and increased sales could positively affect Yuhan's royalty revenue. However, the timing and scale at which prescription expansion translates into actual royalty increases may vary depending on contract terms, sales performance, and settlement methods.
Kiwoom Securities judged that it is necessary to confirm whether the trend of expanding Lazertinib prescriptions becomes more robust. If prescriptions increase in earnest in the global market and royalty revenue expands accordingly, Yuhan's earnings outlook could also change. However, at present, the pace of royalty inflows is falling short of market expectations, weighing on investor sentiment.
■ R&D Achievements and New Technology Transfers Are Also Variables
R&D achievements are another important variable. In addition to Lazertinib, Yuhan is developing various new drug candidates and seeking opportunities for global technology transfers based on its R&D results. The value of a new drug development company is influenced not only by current revenue and operating profit but also by the development stage and commercialization potential of its drug candidates, and technology transfer contracts with global pharmaceutical companies can serve as an important catalyst for converting R&D capabilities into business results. However, technology transfers depend on various factors such as clinical trial results, marketability, the development status of competing drugs, and contract negotiations.
Kiwoom Securities noted that time is needed for Yuhan's R&D achievements to be realized. This is interpreted to mean that additional confirmation processes are required for the results of ongoing R&D projects to be reflected in actual corporate value.
■ "Bottoming Out and Upward Trend Expected if Prescription Expansion and Technology Transfers Are Confirmed"
With the stock price falling to the 70,000-won range, the key to judging the possibility of a rebound lies in Lazertinib's global commercialization performance and whether new technology transfers occur. Kiwoom Securities expected that if a robust trend of expanding Lazertinib prescriptions is confirmed and technology transfer achievements materialize, the stock will bottom out and trend upward. However, this outlook is premised on the condition that future business performance is actually confirmed.
If Lazertinib's sales expansion is slower than expected or new R&D achievements are delayed, stock price recovery may take time. Conversely, if overseas prescription expansion and increased royalty revenue are confirmed, expectations for improved earnings at Yuhan could come back into focus.
Yuhan is a company in the domestic pharmaceutical industry that has pursued new drug R&D and global technology transfers, and Lazertinib's overseas commercialization performance could serve as an important indicator for evaluating its future growth. Given that new drug development companies face a time lag between R&D achievements and actual revenue generation, it is necessary to examine short-term performance and mid- to long-term growth potential separately.
The market is focusing on the pace of Lazertinib prescription expansion and royalty inflow trends. Going forward, Lazertinib's global sales performance, whether running royalties increase, and new technology transfer achievements are expected to act as key variables in Yuhan's stock price movement.
[This article is intended to provide information for investment reference and does not recommend the purchase or sale of any specific stock. Circumstances may vary depending on market conditions. Investment decisions and the responsibility for them rest with the investor. AI provided partial assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Evernos Holdings (XRPN) Flat at $7.45... Bitcoin at $64,922, Market on Alert Over Weakness in Leading Stock](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F626848%2F4c15339f3668573e%2Fvariants%2Fhero.webp&w=1920&q=75)
